Abbott Labs is jumping on the transcatheter mitral valve replacement (TMVR) bandwagon with an agreement to buy out the rest of Tendyne Holdings and an option to Cephea Valve Technologies, both announced July 30.
Abbott will buy the remaining equity of Tendyne that it does not already own for $225m upfront, giving a total...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?